All In MedTech

FDA Clearance Tracker · P040029-S006

Euclid Systems Orthokeratology (oprifoconA)/ Contact Lenses for Overnight Wear/Euclid Systems Orthokeratology (tisilfoco

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 7, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 7, 2019

Approved

Time to decision

677 days

Received Sep 29, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P040029-S006
Device name
Euclid Systems Orthokeratology (oprifoconA)/ Contact Lenses for Overnight Wear/Euclid Systems Orthokeratology (tisilfoco
Applicant location
Sterling, VA
Received
Sep 29, 2017
Decided
Aug 7, 2019
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P040029

Device type

Device class
Class III
Regulation
21 CFR 886.5916
Specialty
Ophthalmology

Every decision under product code NUU

FDA's approval statement

As written in FDA's record.

Approval for new manufacturing site at Euclid Systems Corporation, 45472 Holiday Drive, Suite 7, Sterling, VA.

Source documents

Other decisions for Euclid Vision Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.